SCHEMBL5416362

SCHEMBL5416362

CCCCC(=O)Nc1cnc(Nc2ccc(Cl)c(Cl)c2)nc1NC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STK17A Q9UEE5 2/20 0.46
▸ STK17B O94768 1/20 0.46
▸ HDAC1 Q13547 6/20 0.45
▸ HDAC2 Q92769 5/20 0.45
▸ HDAC6 Q9UBN7 5/20 0.45
▸ HDAC3 O15379 4/20 0.45
▸ PTK2 Q05397 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ JAK2 O60674 3/20 0.43
▸ HDAC4 P56524 2/20 0.43
▸ HDAC7 Q8WUI4 2/20 0.43
▸ HDAC10 Q969S8 2/20 0.43
▸ HDAC11 Q96DB2 2/20 0.43
▸ HDAC8 Q9BY41 2/20 0.43
▸ HDAC9 Q9UKV0 2/20 0.43
▸ HDAC5 Q9UQL6 2/20 0.43
▸ BRD4 O60885 1/20 0.42
▸ ALK Q9UM73 2/20 0.42
▸ MET P08581 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5413822 0.89 CYP3A4 (0.53) STK17ASTK17BHDAC1HDAC2HDAC6
SCHEMBL5416062 0.89 STK17A (0.44) STK17ASTK17BHDAC1HDAC2HDAC6
SCHEMBL5415948 0.84 HDAC3 (0.49) STK17ASTK17BHDAC1HDAC2HDAC6
SCHEMBL5415300 0.83 BRD4 (0.46) STK17ASTK17BHDAC1HDAC2HDAC6
SCHEMBL5408198 0.83 HDAC3 (0.48) STK17ASTK17BHDAC1HDAC2HDAC6
SCHEMBL5415421 0.83 STK17A (0.48) STK17ASTK17BHDAC1HDAC2HDAC6
SCHEMBL5414041 0.82 STK17A (0.44) STK17ASTK17BHDAC1HDAC2HDAC6
SCHEMBL5415230 0.82 EGFR (0.48) STK17ASTK17BHDAC1HDAC2HDAC6
SCHEMBL5418427 0.82 HDAC3 (0.47) STK17ASTK17BHDAC1HDAC2HDAC6
SCHEMBL5410091 0.81 APEX1 (0.53) STK17ASTK17BHDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 STK17A 3301/4885STK17B 3455/4885HDAC1 3995/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 STK17A 3456/4885STK17B 3502/4885HDAC1 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback